CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

Ethereum Foundation Moves $64.4 Million Worth Of ETH, Is This A Dump? – Investorempires.com

Blow as AfDB exits Nairobi waste power plant project on delays – Investorempires.com

Appeals court to hear challenges to potential US TikTok ban on Sept. 16 By Reuters – Investorempires.com